Dorothee Winterberg
Overview
Explore the profile of Dorothee Winterberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, et al.
Blood
. 2024 Mar;
143(26):2735-2748.
PMID: 38518105
Acute lymphoblastic leukemia (ALL) arises from the uncontrolled proliferation of B-cell precursors (BCP-ALL) or T cells (T-ALL). Current treatment protocols obtain high cure rates in children but are based on...
2.
Lutz S, Klausz K, Albici A, Ebinger L, Sellmer L, Teipel H, et al.
Front Immunol
. 2023 Nov;
14:1227572.
PMID: 37965326
The activating receptor natural killer group 2, member D (NKG2D) represents an attractive target for immunotherapy as it exerts a crucial role in cancer immunosurveillance by regulating the activity of...
3.
Spory L, Zimmermann J, Vossen-Gajcy M, Beder T, Bastian L, Alsadeq A, et al.
Hemasphere
. 2023 Sep;
7(9):e945.
PMID: 37670804
No abstract available.
4.
Gehlert C, Rahmati P, Boje A, Winterberg D, Krohn S, Theocharis T, et al.
Front Immunol
. 2022 Sep;
13:957874.
PMID: 36119088
Targeting CD19 represents a promising strategy for the therapy of B-cell malignancies. Although non-engineered CD19 antibodies are poorly effective in mediating complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent...
5.
Lenk L, Winterberg D, Vogiatzi F, Laqua A, Spory L, Mayar A, et al.
Hemasphere
. 2022 Aug;
6(8):e754.
PMID: 35935606
No abstract available.
6.
Vogiatzi F, Heymann J, Muller K, Winterberg D, Drakul A, Rosner T, et al.
Blood Adv
. 2022 Jul;
6(16):4847-4858.
PMID: 35820018
Immunotherapy has evolved as a powerful tool for the treatment of B-cell malignancies, and patient outcomes have improved by combining therapeutic antibodies with conventional chemotherapy. Overexpression of antiapoptotic B-cell lymphoma...
7.
Muller K, Vogiatzi F, Winterberg D, Rosner T, Lenk L, Bastian L, et al.
Blood
. 2022 Apr;
140(1):45-57.
PMID: 35452517
Acute lymphoblastic leukemia (ALL) is the most common malignant disease affecting children. Although therapeutic strategies have improved, T-cell acute lymphoblastic leukemia (T-ALL) relapse is associated with chemoresistance and a poor...
8.
Winterberg D, Lenk L, Osswald M, Vogiatzi F, Gehlert C, Frielitz F, et al.
J Clin Med
. 2021 Jul;
10(12).
PMID: 34203833
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most frequent malignancy in children and also occurs in adulthood. Despite high cure rates, BCP-ALL chemotherapy can be highly toxic. This type...
9.
Baumann N, Rosner T, Jansen J, Chan C, Marie Eichholz K, Klausz K, et al.
Cancer Sci
. 2021 May;
112(8):3029-3040.
PMID: 34058788
Integrin associated protein (CD47) is an important target in immunotherapy, as it is expressed as a "don't eat me" signal on many tumor cells. Interference with its counter molecule signal...
10.
Lenk L, Carlet M, Vogiatzi F, Spory L, Winterberg D, Cousins A, et al.
Commun Biol
. 2021 Jan;
4(1):73.
PMID: 33452446
Central nervous system (CNS) involvement remains a challenge in the diagnosis and treatment of acute lymphoblastic leukemia (ALL). In this study, we identify CD79a (also known as Igα), a signaling...